MedTrace Logo

Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1

NCT04201431 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-11-25

Study results available
· View outcomes & findings →

Summary

This is an Open label, first-in-human, Phase I/IIa, blood-stage P. vivax malaria vaccine trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1 in healthy adults living in the UK.

Conditions

  • Malaria, Vivax

Interventions

BIOLOGICAL

PvDBPII/Matrix-M1

50ug PvDBPII in 50ug Matrix M1

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Angela M Minassian, Dr · Jenner Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-24
Primary Completion
2022-07-14
Completion
2022-07-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04201431 on ClinicalTrials.gov